Dr. Wulf is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
330 Brookline Ave/9th Fl
Beth Isreal Deaconess Med.Ctr.
Boston, MA 02115Phone+1 617-667-0843
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1997 - 1999
St Elizabeth's Medical CenterResidency, Internal Medicine, 1994 - 1997
Westfalischen Landes University Faculty of MedicineClass of 1987
Certifications & Licensure
MA State Medical License 1996 - 2025- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer Start of enrollment: 2007 Apr 01
- Trastuzumab and Vinorelbine in Advanced Breast Cancer Start of enrollment: 2010 Nov 01
- Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer Start of enrollment: 2012 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 92 citationsRac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer.Qingjian Li, Tao Qin, Zhuofei Bi, Huangming Hong, Lin Ding
Nature Communications. 2020-03-19 - 71 citationsCell-to-cell variability in PI3K protein level regulates PI3K-AKT pathway activity in cell populations.Tina L. Yuan, Gerburg M. Wulf, Laura N. Burga, Lewis C. Cantley
Current Biology. 2011-02-08 - 164 citationsOlaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.Panagiotis A. Konstantinopoulos, William T. Barry, Michael J. Birrer, Shannon N. Westin, Karen Cadoo
The Lancet. Oncology. 2019-04-01
Journal Articles
- Effect of Eribulin with or Without Pembrolizumab on Progression-Free Survival for Patients with Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast CancerSara M Tolaney, Gerburg Wulf, Laura Spring, Beth Overmoyer, Ann H Partridge, Eric P Winer, Ian E Krop, JAMA Oncology
Press Mentions
Study Shows Specific Type of Herpes Could Cause Breast CancerAugust 3rd, 2016
Common Virus' Link to Breast Cancer InvestigatedAugust 3rd, 2016
Hub Researchers Uncover Breast Cancer-Mono LinkAugust 3rd, 2016- Join now to see all
Grant Support
- Role Of The Prolylisomerase PIN1 In OncogenesisNational Cancer Institute2002–2007
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
